Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYRRHINIL-INTEST in diarrhea-predominant irritable bowel syndrome (IBS-D)
2019-000307-32Phase 4Active
- Sponsor
- Repha
- Start
- Mar 2020
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing MYRRHINIL-INTEST with Placebo (2 arms). Primary endpoints: Co-primary responder endpoint and Change in stool frequency. Started Mar 2020; status: active.
02
Drugs
Myrrhinil-Intest
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2019-000307-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000307-32.